% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • petruchi0 petruchi0 Apr 4, 2011 1:32 PM Flag

    OGXI- presentation

    OncoGenex announces presentation of data highlighting OGX-427
    OncoGenex Pharmaceuticals announced that preclinical data utilizing their pipeline compound OGX-427 was presented at the AACR 102nd Annual Meeting 2011. The study demonstrated the ability of OGX-427 to inhibit Heat Shock Protein 27, a cell-survival protein believed to play an important role in the proliferation of castrate resistant prostate cancer and resistance to standard therapies. The goal of this study was to test the ability of OGX-427, a second-generation antisense therapy, and other mechanisms in silencing the effects of Hsp27. The study showed that OGX-427 inhibits Hsp27 and therefore a cell survival process called autophagy, to increase intracellular unfolded protein burd en and cause prostate cancer cell death.

0.6203+0.0603(+10.77%)Feb 12 4:00 PMEST